The pharmaceutical landscape often witnesses intense regulatory friction, but the persistent struggle of Aldeyra Therapeutics to secure approval for its dry eye candidate, reproxalap, highlights a particularly challenging journey within the biotech industry. For the third time in as many years, the
The medical community has finally begun to bridge the profound gap between subjective psychological distress and the objective biological markers that have long defined every other branch of clinical medicine. For over a century, psychiatry remained the only medical specialty where a practitioner
Suzanne Harris is a veteran patient advocate and the Senior Vice President of Marketing & Communications at SubjectWell, where she spearheads initiatives to modernize the intersection of clinical research and patient engagement. With a deep focus on patient-centric solutions, she has become a
The global biotechnology sector is currently navigating a pivotal transition as companies move beyond traditional dopamine-replacement therapies to explore more sophisticated neurological pathways. This shift is most visible in the recent strategic expansion of Vima Therapeutics, a Cambridge-based
The intersection of speculative finance and molecular biology creates a high-stakes environment where a single laboratory result can instantly wipe out or multiply a company’s enterprise value by an order of magnitude. Determining the financial worth of an early-stage life sciences company remains o
The silent observations of a caregiver watching a loved one's fingers twitch with newfound intent often stand in stark contrast to the rigid, binary data captured by antiquated medical surveys. While these subtle flickers of regained movement or the first signs of motor decay represent the
